Mesoblast will need to push momentum then ... E.g. EU license deal for Ryoncil or CHF partnership - the latter can't be too far away IMO. I just can't see a CHF partner not wanting to be a part of the BLA submission process including the final FDA pre BLA meeting expected 'shortly' .....
...... no global pharma conglomerate is going to want to tip in the type of $$ Mesoblast is likely now seeking with a AA pathway on offer, which will likely dwarf the previous CHF partnership deal back in 2010, for that indication without substantial involvement in the FDA BLA process (again IMO)
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)